Lactose Intolerance – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032
Lactose intolerance is an impaired ability to digest lactose, a sugar found in milk and other dairy products. Mutations in the LCT gene cause lactose intolerance in infants (congenital lactase deficiency). The LCT gene provides instructions for making the lactase enzyme. A DNA sequence controls LCT gene expression called a regulatory element located within a nearby gene called MCM6.
·
In the Americas, the lactose intolerance
prevalence estimates ranged from 36% in the USA to 80% in Colombia.
Thelansis’s “Lactose Intolerance
Market Outlook, Epidemiology, Competitive
Landscape, and Market Forecast Report – 2021 To 2032" covers disease
overview, epidemiology, drug utilization, prescription share analysis,
competitive landscape, clinical practice, regulatory landscape, patient share,
market uptake, market forecast, and key market insights under the potential Lactose
Intolerance treatment modalities options for eight major markets (USA, Germany,
France, Italy, Spain, UK, Japan, and China).
KOLs insights
of Lactose Intolerance across 8 MM market from the centre of Excellence/
Public/ Private hospitals participated in the study. Insights around current
treatment landscape, epidemiology, clinical characteristics, future treatment
paradigm, and Unmet needs.
Lactose Intolerance Market Forecast Patient
Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs
with sourcing, Market Event, and Product Event, Country specific Forecast
Model, Market uptake and patient share uptake, Attribute Analysis, Analog
Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice
has been established based on a deep understanding of the pharma/biotech
business environment to provide an optimized support system to all levels of
the decision-making process. It enables business leaders in forward-thinking
and proactive decision-making. Thelansis supports scientific and commercial
teams in seamless CI support by creating an AI/ ML-based technology-driven
platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment